Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 14/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17246825 | 0.76 | PARP15 (0.51) | ACACBFFAR1PARP15PARP10 | |
| SCHEMBL7601081 | 0.76 | PARP15 (0.51) | ACACBFFAR1PARP15PARP10 | |
| SCHEMBL19876587 | 0.76 | PARP15 (0.51) | ACACBFFAR1PARP15PARP10 | |
| SCHEMBL20101854 | 0.74 | NAAA (0.40) | — | |
| SCHEMBL20969565 | 0.73 | PARP10 (0.56) | FFAR1PARP15PARP10 | |
| SCHEMBL20969688 | 0.73 | PARP15 (0.54) | FFAR1PARP15PARP10 | |
| SCHEMBL18459838 | 0.72 | SLC5A1 (0.45) | ACACB | |
| SCHEMBL18459837 | 0.72 | SLC5A1 (0.45) | ACACB | |
| SCHEMBL20101851 | 0.71 | NAAA (0.41) | — | |
| SCHEMBL15431280 | 0.68 | DRD4 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118759-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIR USE AS MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118759-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIR USE AS MUTANT IDH1 INHIBITORS | IDH1, IDH3A, IDH3B | GRM2 1489/4885ACACB 1953/4885FFAR1 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.